Nilotinib(continued)
▶Nilotinibis predicted to increase the exposure tocabozantinib.
oTheoretical→Also seeTABLE 15p. 850→Also seeTABLE 9
p. 849
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tonilotinib.oTheoretical
▶Nilotinibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Nilotinibis predicted to increase the exposure toceritinib.
oTheoretical→Also seeTABLE 15p. 850→Also seeTABLE 9
p. 849
▶Nilotinibincreases the concentration ofciclosporin.r
Study
▶Cobicistatis predicted to moderately increase the exposure to
nilotinib. Avoid.rStudy
▶Nilotinibis predicted to increase the exposure tocobimetinib.
rTheoretical
▶Nilotinibis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Nilotinibis predicted to increase the exposure tocorticosteroids
(methylprednisolone). Monitor and adjust dose.oStudy
▶Nilotinibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Nilotinibis predicted to slightly increase the exposure to
darifenacin.oStudy
▶Nilotinibis predicted to increase the exposure todasatinib.
rStudy→Also seeTABLE 15p. 850→Also seeTABLE 9p. 849
▶Nilotinibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Nilotinibis predicted to increase the exposure todopamine
receptor agonists(bromocriptine).rTheoretical
▶Nilotinibis predicted to increase the concentration of
dopamine receptor agonists(cabergoline).oAnecdotal
▶Nilotinibis predicted to moderately increase the exposure to
dutasteride.nStudy
▶Efavirenzis predicted to decrease the exposure tonilotinib.
Avoid.rTheoretical→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure toeliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶Enzalutamideis predicted to moderately decrease the
exposure tonilotinib. Avoid.rStudy
▶Nilotinibis predicted to increase the risk of ergotism when
given withergometrine.rTheoretical
▶Nilotinibis predicted to increase the risk of ergotism when
given withergotamine.rTheoretical
▶Nilotinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Nilotinibis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy→Also see
TABLE 15p. 850
▶Nilotinibis predicted to increase the exposure tofesoterodine.
Adjustfesoterodinedose with moderate inhibitors of CYP3A4
in hepatic and renal impairment.nStudy
▶Nilotinibis predicted to increase the exposure togefitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Grapefruit juiceis predicted to increase the exposure to
nilotinib. Avoid.rTheoretical
▶Nilotinibis predicted to increase the concentration of
guanfacine. Adjustguanfacinedose,p. 231.oTheoretical
▶H 2 receptor antagonistsare predicted to decrease the
absorption ofnilotinib.H 2 receptor antagonistsshould be taken
10 hours before or 2 hours afternilotinib.nTheoretical
▶HIV-protease inhibitorsare predicted to moderately increase
the exposure tonilotinib. Avoid.rStudy→Also seeTABLE 9
p. 849
▶Nilotinibis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to moderately increase the exposure to
nilotinib. Avoid.rStudy→Also seeTABLE 15p. 850
▶Nilotinibis predicted to increase the exposure toivabradine.
Adjustivabradinedose.rTheoretical▶Nilotinibis predicted to increase the exposure toivacaftor.
Adjustivacaftordose with moderate inhibitors of CYP3A4,
p. 186.rStudy
▶Nilotinibis predicted to increase the exposure tolapatinib.
oStudy→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure tolomitapide.
Avoid.oTheoretical
▶Nilotinibis predicted to increase the exposure tolurasidone.
oStudy
▶Macrolides(clarithromycin)are predicted to moderately
increase the exposure tonilotinib. Avoid.rStudy→Also
seeTABLE 9p. 849
▶Macrolides(erythromycin)are predicted to increase the
exposure tonilotinib.oTheoretical→Also seeTABLE 9
p. 849
▶Nilotinibis predicted to increase the exposure tomidazolam.
Monitor side effects and adjust dose.rStudy
▶Nilotinibis predicted to increase the exposure tomidostaurin.
oTheoretical
▶Mitotaneis predicted to moderately decrease the exposure to
nilotinib. Avoid.rStudy→Also seeTABLE 15p. 850
▶Nilotinibis predicted to increase the exposure tonaloxegol.
Adjustnaloxegoldose and monitor side effects.oStudy
▶Netupitantis predicted to increase the exposure tonilotinib.
oTheoretical
▶Nevirapineis predicted to decrease the exposure tonilotinib.
Avoid.rTheoretical
▶Nilotinibis predicted to increase the exposure toolaparib.
Avoid moderate inhibitors of CYP3A4 or adjustolaparibdose.
oTheoretical→Also seeTABLE 15p. 850
▶Nilotinibis predicted to increase the exposure toopioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
adjust dose.oStudy
▶Nilotinibis predicted to increase the exposure toopioids
(methadone, sufentanil).oTheoretical→Also seeTABLE 9
p. 849
▶Nilotinibis predicted to increase the exposure tooxybutynin.
nTheoretical
▶Nilotinibis predicted to increase the exposure topazopanib.
oTheoretical→Also seeTABLE 15p. 850→Also seeTABLE 9
p. 849
▶Nilotinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Nilotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(avanafil). Adjustavanafil
dose.oTheoretical
▶Nilotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(sildenafil). Monitor or
adjustsildenafildose with moderate inhibitors of CYP3A4,
p. 120.oStudy→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(tadalafil).rTheoretical
▶Nilotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(vardenafil). Adjust dose.
rTheoretical→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure topimozide.
Avoid.rTheoretical→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure toquetiapine.
Avoid.oStudy
▶Nilotinibis predicted to increase the exposure toranolazine.
rStudy→Also seeTABLE 9p. 849
▶Nilotinibis predicted to increase the exposure toribociclib.
oStudy→Also seeTABLE 9p. 849
▶Rifampicinis predicted to moderately decrease the exposure
tonilotinib. Avoid.rStudy
▶Nilotinibis predicted to increase the exposure toruxolitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Nilotinibis predicted to increase the exposure tosaxagliptin.
nStudy
▶Nilotinibis predicted to increase the exposure tosimeprevir.
Avoid.rStudy
▶Nilotinibincreases the concentration ofsirolimus. Monitor and
adjust dose.oStudy964 Nilotinib—Nilotinib BNFC 2018 – 2019
Interactions|Appendix 1A1